Outcomes of older men receiving docetaxel for metastatic hormone-sensitive prostate cancer.

ABSTRACT:

Background

Most men who die of prostate cancer are older than 70 years. The ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer (CHAARTED) randomized men of all ages with metastatic hormone-sensitive prostate cancer (mHSPC) to receive androgen deprivation therapy (ADT) with or without docetaxel demonstrating an overall survival (OS) benefit for docetaxel.

Methods

In a post-hoc analysis of this trial, we assessed patient characteristics and OS in patients ≥70 years ("older men") versus <70 years ("younger men") with Cox proportional hazards models. In addition, we compared adverse events, therapy completion rate, and subsequent treatment patterns between these two groups using Chi-squared tests.

Results

177 (22.4%) p

SUBMITTER: Lage DE 

PROVIDER: S-EPMC8599519 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature